Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_assertion type Assertion NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_head.
- NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_assertion description "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_provenance.
- NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_assertion evidence source_evidence_literature NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_provenance.
- NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_assertion SIO_000772 21185263 NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_provenance.
- NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_assertion wasDerivedFrom befree-2016 NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_provenance.
- NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_assertion wasGeneratedBy ECO_0000203 NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_provenance.